TABLE 7.
Study | Agent | VRC vaccine | Antigen | Titer |
---|---|---|---|---|
Study V | Ebola virus | Product 12 | GP-Zaire | ≥ 6400 |
NP | ≥ 6400 | |||
Study VI | SARS virus | Product 15 | Spike | ≥ 10,000 |
Study VII | West Nile virus | Product 17 | PreM and E | ≥ 10,000 |
Study | Agent | VRC vaccine | Antigen | Titer |
---|---|---|---|---|
Study V | Ebola virus | Product 12 | GP-Zaire | ≥ 6400 |
NP | ≥ 6400 | |||
Study VI | SARS virus | Product 15 | Spike | ≥ 10,000 |
Study VII | West Nile virus | Product 17 | PreM and E | ≥ 10,000 |